Nuvation Bio Inc.
corporate_fare Company Profile
Nuvation Bio Inc. (NYSE:NUVB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 20 items for NUVB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-17, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 16 rated 8 or above. Recent SEC coverage for NUVB spans 10-Q, 8-K, 424B5, FWP.
Recent high-impact activity:
- FDA Approves IBTROZI Label Update with 49.7-Month Duration of Response in ROS1+ NSCLC
- FDA Grants Fast Track to Nuvation Bio's Safusidenib for IDH1-Mutant Glioma
- Nuvation Bio Q2 Revenue Beats Estimates as IBTROZI Sales Jump 25%
- Nuvation Bio Q2 Revenue Beats Consensus, CEO Adopts 10b5-1 Plan, Pipeline Advances
- Nuvation Bio Completes $287.5M Convertible Note Offering with Full Greenshoe Exercise
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for NUVB, detected from its recent SEC filings · based on capital-structure filings through 2026-07-06.
Finalized Convertible Note Offering · Premium Conversion Price
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →